cover-dec-2016
Prescriber is the leading UK journal for healthcare professionals focussing on prescribing and medicines management. The journal features articles on all areas of therapeutics and prescribing policy and is fully peer reviewed. The content is relevant and of interest to all prescribers and prescribing policy makers including GPs, pharmacists, nurses and hospital specialists. Access to all content is free to healthcare professionals following registration.Sign up for e-alerts and print copies

Latest News

CMA fines Pfizer and Flynn Pharma record-breaking £90 million

The Competition and Markets Authority (CMA) has fined Pfizer and Flynn Pharma a record-breaking £90 million for overcharging the NHS for an anti-epileptic...Read more

New guidance on severe mental illness and substance misuse

NICE has published a new guideline on co-existing severe mental illness and substance misuse: community health and social care services (NG58). The guideline...Read more

NICE recommends mepolizumab for severe eosinophilic asthma

In draft guidance, NICE has recommended mepolizumab (Nucala) as an add-on to optimised standard therapy for treating severe refractory eosinophilic asthma in...Read more

New NICE guideline on low back pain and sciatica

NICE has published a new guideline (NG59) on the assessment and management of low back pain and sciatica in people over 16 years old. The guideline replaces...Read more

Biological monotherapy effective for rheumatoid arthritis

A recent Cochrane Review has assessed the benefits and harms of monotherapy using biological agents in adults with rheumatoid arthritis (Cochrane Database of...Read more

Featured Articles

More clarity needed on the true benefits and risks of statins
The benefits and risks of statins have recently been the subject of much controversy and debate. Dr Malhotra and colleagues argue that selective reporting and publication bias may be overestimating the efficacy and underestimating the side-effects of statins.
Click here to view

SGLT2 inhibitors and risk of genitourinary infections
The SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin are now becoming established in the management of type 2 diabetes, but they are associated with an increased risk of genital and urinary tract infections…
Click here to view

Recommended management of thyroid disorders
Most cases of primary hypothyroidism can be managed in general practice but thyrotoxicosis requires referral for an accurate diagnosis before treatment can be commenced.
Click here to view

Web design and marketing agency Leamington Spa